5-(chloromethyl)-1,3-dimethyl-1H-pyrazole → 1-((1,3-dimethyl-1H-pyrazol-5-yl)methyl)-3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-5,5-dimethylimidazolidine-2,4-dione

Beteiligte Stoffe

Rolle	Name	HCID	Einwaage
Edukt	5-(chloromethyl)-1,3-dimethyl-1H-pyrazole	HCID 4961270	—
Edukt	3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-5,5-dimethylimidazolidine-2,4-dione	HCID 59524388	—
Produkt	1-((1,3-dimethyl-1H-pyrazol-5-yl)methyl)-3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-5,5-dimethylimidazolidine-2,4-dione	HCID 53373958	—

Reaktionsschritte

Prepared as in Example 12-16 from 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-5,5-dimethylimidazolidine-2,4-dione (Example 12-16a) and 5-(chloromethyl)-1,3-dimethyl-1H-pyrazole. MS 412 (MH+). The title compound was shown to inhibit hT2R08 bitter receptor and had an 1050 of 0.23 μM.

Herkunft & Nachweise

DOI	10.6084/m9.figshare.5104873.v1
Patentnummer	US09247759B2
Quelldatensatz	uspto-grants-2016_02
ORD ID	ord-660c4cb76b444b9181d39aaa2392c08e
Quellennotiz	uspto-grants-2016_02